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CARLSON, M. D., J. B. PENNEY, JR. AND A. B. YOUNG. NMDA, AMPA, and benzodiazepine binding site changes in Alz- 
heimer's disease visual cortex. NEUROBIOL AGING 14(4) 343-352, 1993.--Quantitative receptor autoradiography was used to 
measure the laminar distribution of [3H]glycine and [3H]glutamate binding to the N-methyl-D-aspartate (NMDA) receptor complex, 
[3H]D,L-ct-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) binding to the AMPA receptor, and [3H]flunitrazepam 
binding to the benzodiazepine (BDZ) receptor in three areas of visual cortex in control and Alzheimer's disease (AD) postmortem 
human brains (primary or striate visual cortex, visual association cortex, and higher-order visual association cortex, corresponding to 
Brodmann Areas 17, 18, and 21, respectively). In Area 17, binding to the NMDA, AMPA, and BDZ receptors was not significantly 
altered in the AD brains (except in layer VI for [aH]glycine and layer III for [3H]AMPA, where binding was reduced in the AD brains). 
Ligand binding to the two EAA receptors in Area 18 was, however, significantly reduced in the AD brains (layers I through III for 
[3H]glycine and layers UI through VI for [3H]AMPA). In Area 21, binding to both the NMDA and BDZ receptors but not to the AMPA 
receptor, was significantly reduced in almost all laminae of the AD brains (layers I through VI for [3H]glycine and layers I through 
V for [aH]flunitmzepam). This hierarchical pattern of laminar binding loss with increasing complexity of association visual cortices 
is consistent with the increasing numbers of neurofibrillary tangles found in those areas, implicating NMDA and BDZ receptor bearing 
cells in AD neuropathology. AMPA receptor losses do not parallel the pathology, suggesting that AMPA receptors are not directly 
correlated with the pathology. 
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ALZHEIMER'S disease (AD), is marked by cortical dementia, 
memory loss, personality changes, and signs of cortical discon- 
nection (2). The characteristic neuropathology of AD is the abun- 
dance of neurofibriUary tangles (NFT's) and amyloid-containing 
neuritic plaques (NP's) in the cerebral cortex and hippocampus 
(29). N F r ' s  represent the accumulation of abnormal paired helical 
filaments in the cytoplasm of neurons, whereas NP's are com- 
prised of dystrophic neurites and glial processes, with or without 
an amyloid core (68). In the cerebral cortex, NFT's are found 
primarily in pyramidal neurons and both NFF's  and NP's are 
thought to be more common in association cortex than in the 
primary sensory regions (for reviews see 4,5,28,53,55,66). In 
addition to the accumulation of NFT's,  the large pyramidal cells of 
the cerebral cortex become significantly depleted in AD (36,67). 
In a study by Lewis et al (34), the regional and laminar distri- 
bution of NFF's  were found to be strikingly similar to the known 
distribution of corticocortical pyramidal neurons in the visual cor- 
tex of AD brains, whereas NP's had a less specific regional and 
laminar distribution (4,5). Pyramidal neurons (found mainly in 
layers III and V) furnish the long corticocortical projections re- 
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343 
quired for the intricate connections between appropriate areas of 
cerebral cortex. It is thought that the dementia of AD results from 
the degeneration of these long corticocortical projection neurons 
and the loss of the connections they furnish (49). It was also 
determined in the study of Lewis et al. (34) that the number of 
NFT's was very low in primary striate cortex (primary visual, 
Area 17 but increased 20-fold in the immediately adjacent visual 
association cortex (secondary visual, Area 18), and showed a fur- 
ther doubling in the next higher-order visual association cortex 
(tertiary visual, Areas 19, 20, 21). Thus, the number of N F r ' s  
progressively increased across primary, association, and higher- 
order association visual cortex in a manner which parallels their 
position in the proposed hierarchical organization of the visual 
cortex (70,71). This hierarchical pattern of increasing NFT vul- 
nerability within successive areas of the cerebral cortices appears 
to be correlated with the hierarchies of corticocortical connections 
(4,15). 
Excitatory amino acids (EAA's) are thought to be the principal 
excitatory neurotransmitters of cortical neurons (9,11,14,16,19, 
23,64,69). Abundant evidence from neurochemical, electrophys- 
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iological, immunocytochemical, and transport studies indicate that 
the pyramidal neurons comprising corticocortical association, cor- 
ticofugal, and some intracortical projections utilize glutamate as 
their primary EAA neurotransmitter (for a review see ref. 69). In 
addition, the EAA receptors of some of these cortical pathways 
have been characterized (1,23,26,44,58,69). 
Recent interest has focused on the potential role of EAA's in 
AD and the pathologic role of EAA's as excitotoxins has received 
a tremendous amount of attention (for reviews see refs. 
10,17,23,31,38,39,40,51). Several studies have shown that exci- 
totoxins can induce the formation of abnormal cytoskeletal pro- 
teins, paired helical filaments (NFr 's) ,  and NP's resembling those 
seen in AD brains (3,12,31,39,40). NFT's have been found in 
glutamate-immunoreactive neurons (32). 
The NMDA subtype of EAA receptor, by nature of its effects 
on calcium and its propensity to cause neurotoxicity, has been 
hypothesized to play a role in the neurodegeneration of AD (7, 
23,24,31,39,40,45,54). Furthermore, the glycine modulatory site 
of the NMDA receptor has been proposed as an attractive target for 
potential therapeutic regulation of EAA neurotransmission in AD 
(8,57,58,59). Glutamatergic denervation and possible abnormal 
metabolism in AD has recently been shown (56). Selective reduc- 
tions in EAA receptor levels in the cortex and hippocampus of AD 
also suggest a possible role for EAA neurotransmitters in the 
pathogenesis of the disease (13,21,22,27,37,54,57,58,59). 
In a recent study, specific laminar alterations in non-EAA re- 
ceptors in AD cingulate cortex were found, suggesting that heter- 
ogeneities in cortical AD neuropathology are reflected in the lam- 
inar patterns of binding to postsynaptic receptors (72). Anatomical 
studies indicate that the characteristic pathology of AD distributes 
in relation to EAA cortical association pathways (53,60). To fur- 
ther characterize the role of EAA's in the cortical pathways dis- 
rupted in AD, we examined the laminar distribution of [3H]glycine 
and [3H]glutamate binding to the NMDA receptor, [3H]AMPA 
binding to the AMPA receptor, as well as [3H]flunitrazepam bind- 
ing to the non-EAA benzodiazepine (BDZ) receptor using quan- 
titative receptor autoradiography in three areas of visual cortex 
(primary, association, and higher-order association) in control and 
AD postmortem human brains. 
EXPERIMENTAL PROCEDURES 
Tissue Preparation 
Brains of 8 individuals who had died with AD and 8 nonde- 
mented controls were obtained at necropsy. AD pathology was 
defined according to previous neuropathologic criteria (29). The 
postmortem delay and age at death were matched so that the con- 
trol and AD brains were not significantly different; the average 
postmortem delay was 16 --- 4 (SD) h for the controls (range 12-24 
h) and 14 -+ 6 h for the AD cases (range 7-22 h). The average age 
at death was 72 - 6 years for the controls (range 64- 82 years) and 
73 --- 9 years for the AD brains (range 61-82 years). The brains 
were sectioned in a coronal plane, cut into slabs, frozen in crushed 
dry ice, placed in sealed plastic bags, and stored at -70°C. For 
this study, the slabs were brought from - 7 0  ° to -20°C and 
blocks containing either occipital lobe containing the caicarine 
fissure, corresponding to primary and association visual cortex 
(Brodmann Areas 17 and 18), or posterior middle temporal gyrus, 
corresponding to higher-order visual association cortex (Brod- 
mann Area 21), were cut by JBP and presented to the other in- 
vestigators as coded samples. These blocks were coated with Lip- 
shaw embedding matrix, placed in zip-lock plastic bags, and 
stored at -70°C until the time of the experiment. All binding 
assays and data analyses were completed before the code was 
broken and the statistical comparisons made. 
On the day prior to assay, the blocks of occipital and temporal 
cortex were brought from - 7 0  ° to -20°C by placement in a 
-20°C freezer overnight, mounted on cryotome chucks, and se- 
rial sections (20 microns thick) cut on a Lipshaw cryostat. The 
sections were then thaw-mounted onto twice gelatin-coated slides 
and stored at - 20°C. All assays were performed within 2 days of 
sectioning. Additional sections were cut for cresyl violet and 
thioflavine S staining (see below). 
Materials 
D,L-c~-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), strychnine HC1, and 3-(2-carboxypiperazin-4-yl)propyl- 
1-phosphonic acid (CPP) were obtained from Research Biochem- 
icals Inc. (Natick, MA). [3H]Glycine, L-jail]glutamate, and 
[3H]flunitrazepem were purchased from Amersham (Arlington 
Heights, IL) specific activities of 19.1, 45, and 83 Ci/mmol, re- 
spectively). [3H]AMPA was obtained from NEN-Dupont (Boston, 
MA; specific activity 60 Ci/mmol). Quisqualic acid was purchased 
from Cambridge Research Biochemicals (Valley Stream, NY). All 
other chemicals were purchased from Sigma (St. Louis, MO). 
[3H]Glycine Binding Assay 
The glycine modulatory site (strychnine-insensitive) of the 
NMDA-receptor complex was assayed using a modified version of 
the method used for rat brain by McDonald et a1.(43). Briefly, 
sections were prewashed in 50 mM Tris-C1 buffer (pH 7.4) at 25°C 
for 30 min and then dried with cool air. The sections were then 
immersed in cytomailers containing 4°C Tris-C1 buffer, 100 nM 
[3H]glycine (Amersham, S~A. 19.9 Ci/mmol) and 1 mM strych- 
nine (chloride salt). Preliminary experiments determined that these 
prewash and buffer conditions were optimal for a high ratio of 
specific to nonspecific [3H]glycine binding in the human tissue. 
Nonspecific binding was determined in the presence of 1 mM 
unlabelled glycine and represented less than 10% of total binding. 
After a 35-min incubation period at 4°C to allow binding to occur, 
the sections were rapidly rinsed four times with 4 ml each of 4°C 
Tris-Cl buffer only. The sections were then dried under a stream of 
cool air (total rinse time was less than 10 s). This rinse protocol 
was also determined to be optimal for specific [3H]glycine binding 
in the human brain tissue used for this study (laminated visual 
cortex). A similar method for assaying the strychnine-insensitive 
[3H]glycine binding site in human tissue autoradiographically has 
been reported (26,27). 
Other Ligand Assays 
The NMDA site of the NMDA-receptor complex was assayed 
as NMDA-sensitive [3H]glutamate binding in the presence of sat- 
urating amounts of quisqualate and kainate using a modification of 
the protocols of Greenamyre et al. (20) and Penney et al. (54). 
Briefly, following a 30-min prewash at 4°C, sections were incu- 
bated in cytomailers (4°C) with 65 nM [3H]glutamate plus 2.5 mM 
quisqualate and 1 mM kainate in 50 mM Tris-acetate buffer (pH 
7.4). 3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP, 
100 mM) was used to determine nonspecific binding. Sections 
were then rinsed four times with 4 ml each of 4°C Tris-acetate 
buffer, followed by two rinses of 2 ml each of 2.5% glutaralde- 
hyde in acetone (4°C) and drying. 
D,L-c~-amino- 3 -hydroxy-5 -methyl-4-isoxazolepropionic acid 
([3H]AMPA, 10 nM) was used to assay binding to the AMPA 
receptor in 50 mM Tris-C1 buffer containing 2.5 mM CaC12 and 30 
mM KSCN (pH 7.2) essentially as described above for the NMDA 
receptor, using 1 mM L-glutamate to determine nonspe- 
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cific binding (46,50,74). All assays were run in triplicate for the 
totals and duplicate for the nonspecific binding. 
[3H]Flunitrazepam (10 nM) was used to measure binding to the 
BDZ (benzodiazepine) receptor (54,73). Briefly, sections were 
washed in 50 mM Tris-citrate buffer (pH 7.0) three times for 5 min 
each at 4°C, dried under a stream of cool air and exposed to ligand 
buffer for 30 rain at 4°C. Following incubation the sections re- 
ceived one quick dip in buffer (4°C) followed by two 5 min rinses 
in buffer and a quick dry under hot air. Clonazepam (2 mM) was 
used to determine nonspecific binding. 
Quantification of Receptor Binding 
Upon completion of the assays, the slides were cut and taped 
onto sheets, apposed to tritium sensitive film (Amersham Hyper- 
film) in sealed cassettes along with known radioactive standards 
(~4C) and exposed for 10 days to 4 weeks at -20°C.  The films 
were developed in Kodak D-19 and binding levels were quanti- 
tated in each of the cortical areas with computer assisted densi- 
tometry using the MCID system (Imaging Research, Inc., St. 
Catharines; Ontario). Using this system, optical density values 
were converted to pmol/mg protein using a computer generated 
polynomial regression analysis which compared film densities pro- 
duced by the tissue sections to those of the known radioactive 
standards (52). Cresyl violet-stained adjacent sections (see below) 
were used as templates to delineate the six layers of each cortical 
area; multiple readings were taken and averaged in each layer of 
the overlaid autoradiograph using a variable size cursor. Cortical 
layers were classified according to the cytoarchitectonic scheme of 
Horton and Hedley-Whyte (25). It was possible to delineate layers 
I from II, II from III, III from IV or IVb, IVb from IVc, IVc or IV 
from V, V from VI, and VI from subcortical white matter in the 
autoradiograms. Ligand binding in these layers was determined in 
three separate cortical areas: primary visual cortex (Brodmann 
Area 17), visual association cortex (Brodmann Area 18), and the 
higher-order visual association cortex (Brodmann Area 21). All 
data presented were analyzed densitometrically from the autora- 
diograms. The level of binding of each ligand in each layer of the 
three cortical areas of the control samples were compared to those 
in the AD samples using a student t test (unpaired, et = 0.05). 
Histology 
Cresyl violet staining histochemistry was carried out as fol- 
lows. Sections adjacent to those used for autoradiography were 
fixed over paraformaldehyde vapor for a minimum of 48 h, stained 
with 0.5% cresyl violet, dehydrated in graded alcohols and xylene, 
and coverslips affixed with Permount (Fisher). Additional 
paraformaldehyde fixed sections were stained with 0.1% Thiofla- 
vine S for 13-amyloid protein. These sections were analyzed using 
a fluorescent microscope to count the number of NFrs  and NPs 
(neuritic plaques) in the Alzheimer's sections. The number of 
NFTs and NPs in each layer of each area were compared by 
ANOVA with post hoc comparisons. 
RESULTS 
The number of senile plaques and neurofibrillary tangles in 
each layer of the different regions of the Alzheimer's brains are 
shown in Table 1. There were significant differences [p < 0.0001; 
two-way analysis of variance (ANOVA)] in the number of plaques 
in the different layers but not in the different areas. The number of 
plaques in layers 3 and 5 was higher than in the other layers (p < 
0.05 by Fischer PLSD). The number of tangles in layer 5 were 
significantly different in the different areas (p < 0.02 by ANOVA) 
with the higher-order association cortices having more tangles. 
The laminar pattern of NMDA, AMPA, and BDZ binding 
clearly distinguished primary striate visual cortex (Brodmann Area 
17) from the surrounding visual association cortex (Brodmann 
Area 18) and higher-order visual cortex (Brodmann Area 21). As 
others have reported (1,26) in Area 17, layer IVb binding was very 
low due to tritium absorption by the white matter in the line of 
Gennari. This decrease in layer IV binding was much less evident 
in Areas 18 and 21. The other major difference between the 
ligands was in the higher synaptic density in layer IVc that is not 
present in Areas 18 and 21. The ligands differed greatly in their 
amount of binding to this layer. NMDA and glycine binding sites 
showed similar patterns of laminar densities whereas the patterns 
of these two binding sites were different from AMPA and BDZ 
binding by three-way ANOVA; AMPA and BDZ binding patterns 
were different also. The details of this binding and the differences 
between control and AD are given below. 
[3H]Glycine Binding 
Glycine binding to the NMDA receptor complex was found 
heterogeneously distributed across all laminae of each area of vi- 
sual cortex examined. In the primary visual cortex (Brodmann 
Area 17, Figs. 1 and 2A), glycine binding was highest in layer 
IVc, moderately high in layers II, III, and somewhat lower in 
layers I, IVb, V, and VI. In all six layers of the primary visual 
cortex, the [3H]glycine binding levels were slightly reduced in the 
AD brains; however, only in layer VI did the data reach statistical 
significance. In visual association cortex (Brodmann Area 18, 
Figs. 1 and 3A), glycine binding was highest in layers II and III, 
and lower in layers I, IV, V, and VI. In this area of visual cortex, 
TABLE 1 
NUMBER OF SENILE PLAQUES AND NEUROFIBRILLARY TANGLES PER 1 mm 2 FIELD IN VISUAL CORTEX OF 
THE ALZHEIMER'S DISEASE BRAINS 
Senile Plaques (Mean --. SD) Neurofibrillary Tangles (Mean --. SD) 
Area 17 Area 18 Area 21 Area 17 Area 18 Area 21 
Layer 1 1.3 --- 1.8 1.8 ± 1.5 2.9 --- 2.6 0.2 - 0.4 0 0 
Layer 2 3.3 --- 6.7 3.8 + 2.6 3.8 --- 1.2 3.5 ± 8.1 4.7 --- 5.2 6.5 ± 5.0 
Layer 3 5.7 --- 7.2 9.2 ± 5.7 7.5 --- 3.7 2.2 --- 5.3 5.8 --- 12. 5.9 --- 3.1 
0 
Layer 4 2.0 --- 2.8 1.7 --- 1.8 1.8 --- 1.7 0 1.0 ± 2.5 0.4 --- 0.5 
Layer 5 4.0 ± 3.2 5.2 -+ 4.0 5.6 ± 2.0 0 6.0 ± 7.9 9.5 -4- 5.7* 
Layer 6 1.7 --- 2.6 3.0 ± 2.7 3.4 ± 2.1 0.8 ± 2.0 2.7 ± 3.0 2.1 ± 1.7 
* Significantly greater than Area 17 (p < 0.05) by ANOVA with post-hoc Sch6ff~ test. 
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FIG. 1. Representative autoradiograms showing the binding of 100 nM [3H]glycine (top), 65 nM [3H]glutamate under NMDA- 
preferring conditions (upper), 10 nM [3H]AMPA (lower) and 10 nM [3H]flunitrazepam (bottom) to Areas 17 and 18 of nearly 
adjacent sections from a representative control (left) and AD (right) occiptal cortex. Layer IVc of Area 17 is easily distinguishable 
as a layer of dense binding in the [3H]glycine, [3H]glutamate, and [3H]flunitrazepam autoradiograms and as a layer of low binding 
(along with layer IVb) in the [3H]AMPA autoradiograms. 
glycine binding in layers I, II, and III was significantly reduced 
(approximately 30%) in the AD brains, although binding in all 
layers was somewhat lower in the AD brains. In the higher-order 
visual association cortex (Brodmann Area 21, Figs. 4 and 5A), 
glycine binding was significantly reduced (approximately 30%) in 
all laminae of the AD brains. Thus, there was an increasing re- 
duction in glycine binding as one went from primary visual cortex 
to visual association cortex to higher-order association visual cortex. 
NMDA-Sensitive [3H]Glutamate Binding 
The laminar pattern of NMDA-sensitive [3H]glutamate binding 
in the primary visual cortex was very similar to that found for 
[3H]glycine (i.e., highest binding was found in layer IVc, mod- 
erately high binding in layers II, III, and lower binding in layers I, 
IVb, V, and VI, Figs. 1 and 2B). In fact, in all three areas of visual 
cortex examined, [3H]glycine and [3H]glutamate showed parallel 
distributions in their laminar binding pattern, supporting the notion 
that the two ligands are simply binding to different sites on the 
same NMDA receptor complex. Other studies in postmortem hu- 
man cortex have also demonstrated a high degree of congruence 
between the binding patterns of [3H]glycine and [3H]glutamate, 
consistent with the notion that these ligands bind to different re- 
gions of the same NMDA receptor complex (26). Furthermore, 
[3H]glutamate binding to the NMDA receptor complex in this 
study followed the same trend as glycine binding in the AD brains 
(i.e., the patterns of change of the two ligands were not signifi- 
cantly different by two-way ANOVA); that is, a progressive de- 
crease in binding is seen in the AD brains in the visual association 
cortices, although the data did not reach statistical significance 
(Figs. 1, 2B, 3B, 4, and 5B). 
[3H]AMPA Binding 
The laminar distribution of [3H]AMPA binding differed from 
that of the two NMDA receptor ligands. [3H]AMPA binding was 
highest in layers II and III of primary visual cortex and relatively 
low in layer IVc (Figs. 1 and 2C). In layer II of primary visual 
cortex, [3H]AMPA binding was significantly reduced (approxi- 
mately 35%) in the AD brains, although binding in all laminae was 
slightly lower. In the visual association cortex (Figs. 1 and 3C), 
[3H]AMPA binding remained highest in layers II and III but in the 
AD brains was significantly reduced in layers III, IV, V, and VI. 
In the higher-order visual association cortex, however,  
[3H]AMPA binding was not significantly altered in any layer of 
the AD brains (Figs. 4 and 5C). Therefore, the laminar pattern of 
[3H]AMPA binding in the three areas of visual cortex studied 
differed from that of the NMDA receptor complex. This may 
reflect the different pattern of distribution or density of the two 
EAA receptor types in these cortical laminae. 
[3H]Flunitrazepam Binding 
[3H]Flunitrazepam binding to the benzodiazepine receptor gave 
a somewhat different pattern than that of the two EAA receptors 
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FIG. 2. Primary Visual Cortex: Area 17. Histograms of autoradiographic binding to primary visual (striate) 
cortex, Brodmann Area 17, for each ligand assayed. (A) 100 nM [3H]glycine binding; (B) NMDA-sensitive 
65 nM [3H]glutamate binding; (C) 10 nM [3H]AMPA binding; (D) 10 nM [3H]flunitmzepam binding. Error 
bars represent the SEM. *p < 0.05 and **p < 0.01, in comparing Alzheimer's to control brains by unpaired 
student t test. 
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FIG. 3. Visual Association Cortex: Area 18. Histograms of autoradiographic binding to visual association 
cortex, Brodmann Area 18, for each ligand assayed. (A) 100 nM [3H]glycine binding; (B) NMDA-sensitive 
65 nM [3H]glutarnate binding; (C) 10 nM [3H]AMPA binding; (D) 10 nM [3H]flunitrazepam binding. Error 
bars represent the SEM. *p < 0.05 and **p < 0.01, in comparing Alzheimer's to control brains by unpaired 
student t test. 
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FIG. 4. Representative autoradiograms showing the binding of 100 nM [3H]glycine (top), 65 nM [~H]glutamate under NMDA- 
preferring conditions (upper), 10 nM [3H]AMPA (lower) and 10 nM [3H]flunitrazepam (bottom) to Area 21 of nearly adjacent 
sections from a representative control (left) and AD (right) posterior temporal lobe. 
examined. In primary visual cortex, [3H]flunitrazepam binding 
was highest in layers II1 and IVc, with lower binding in layers 1, 
II, IVb, V, and VI (Figs. 1 and 2D). In the association cortices, 
[3H]flunitrazepam binding remained highest in layer III (Figs. 1, 
3D, 4 and 5D). In contrast to the EAA receptors, [3H]fluni- 
trazepam binding had a nonsignificant trend of slightly higher in 
the AD brains in primary visual cortex. The binding of [3H]fluni- 
trazepam in visual association cortex was only slightly reduced in 
the AD brains. In the higher-order visual association cortex, how- 
ever, [3H]flunitrazepam binding was significantly reduced in lay- 
ers I through V of the AD brains. 
DISCUSSION 
Summary of Results and Comparison With Other Studies 
In this study, a hierarchical pattern of receptor binding vulner- 
ability in AD was examined at successive levels of visual cortex. 
The hierarchical pattern was most obvious for [3H]glycine binding 
to the NMDA receptor, although a parallel trend was obtained for 
NMDA-sensitive VH]glutamate binding, where increasing reduc- 
tions in laminar binding were found at each higher level of asso- 
ciation cortex. The pattern of glycine binding loss paralleled the 
increase in AD neuropathology (NFT number) seen in primary, 
association, and higher-order association visual cortex (4,34). 
Binding to the AMPA receptor was reduced as well but only at the 
first level of visual association cortex (Brodmann Area 18), 
whereas the BDZ receptor binding pattern was reduced only in the 
highest-order level of visual association cortex (Brodmann Area 21). 
The results obtained in our study for the laminar distribution of 
[3H]glycine and [3H]glutamate binding to the NMDA receptor, as 
well as [3H]AMPA binding to the AMPA receptor, in human 
primary visual cortex are very similar to those first obtained by 
Jansen et al. (26) and Albin et al. (1), although different cytoar- 
chitectonic schemes were used in the two studies. The cytoarchi- 
tectonic scheme incorporated by Jansen et al. was developed for 
the macaque visual cortex (35) and includes both a layer IVa as 
well as a subdivision of layer 1Vc into IVca and IVcb. Thus, 
differences between our studies and that of Jansen et al. (26) lie in 
the assignment of cortical laminae. In our studies, we used the 
cytoarchitectonic scheme of Horton and Hedley-Whyte (25), 
which was developed for the human striate visual cortex and which 
does not include a layer IVa or the subdivision of layer IVc into a 
and b. In addition, our study further examines EAA receptor bind- 
ing parameters at higher levels of visual association cortex and 
compares the control data to that of AD brains. Binding to the 
BDZ receptor was also included in our study, and our results were 
found to be comparable to those obtained by other groups for 
human primary visual cortex (61,75). Thus, the laminar distribu- 
tions of EAA and BDZ receptors are quite distinctive in the human 
visual cortex, suggesting that the pattern of EAA and non-EAA 
neurotransmission may vary from layer to layer in each area of the 
visual hierarchy. The results provided in our study contribute ad- 
ditional information about which types of EAA receptors in the 
visual hierarchy are selectively vulnerable in AD. 
Visual Cortex, AD Neuropathology, and Excitatory Amino Acids 
The human visual system is a complicated array of networks 
interconnecting many levels of association cortices. Recent studies 
EAA FINDING IN ALZHEIMER'S VISUAL CORTEX 349 
bt , 
• OA 
i o - J o  
IT/I- I z ~  ~ °"1 I l i.. o., 
ItlE||||I I :" 
~ " ~  02 z~¢3 0.1 
ip~ u,IZ 
< z  
0 0 ~  ~ "  O 0  
I II III IV V VI 
Oi 
" °  ii a . E  l e  
O.O 
I II III IV V Vl I II III IV V Vl 
• Control 
[ ]  Alzrlelmer 
FIG. 5. Higher-Order Visual Association Cortex: Area 21. Histograms of autoradiographic binding to 
higher-order visual association cortex, Brodmann Area 21, for each ligand assayed. (A) 100 nM [3H]glycine 
bindng; (B) NMDA-sensitive 65 nM [3H]glutamate binding; (C) 10 nM [3H]AMPA binding; (D) 10 nM 
[3H]flunitrazepam binding. Error bars represent the SEM. *p < 0.05 and **/7 < 0.01, in comparing 
Alzheimer's to control brains by unpaired student t test. 
propose the existence of an elaborate hierarchical processing 
stream to explain the various connections of the association cor- 
tices of the visual system (15,41,70,71). 
Interestingly, a similar hierarchical pattern of neuropathology 
has recently been discovered in AD visual cortex (4,34). In these 
studies, NFI"s found in pyramidal neurons increase in number at 
each step of the hierarchy from primary visual cortex to higher 
levels of visual association cortices. There appears to be a pattern 
of selective vulnerability in the neuropathological pattern of cor- 
tical neurodegeneration in AD visual cortex as evidenced with the 
increasing numbers of NFT's. The findings from these studies may 
provide an anatomical basis for the loss of intellectual functions in 
AD and are consistent with the hypothesis that the dementia in AD 
results from the loss of the structural and functional integrity of the 
long corticocortical projection systems (34,49,53). 
Abundant evidence exists for the role of EAA's in the visual 
cortex (9,26,30,42,61). These studies indicate that the pyramidal 
neurons comprising corticocortical association fibers, such as 
those found in the visual cortex, utilize glutamate as their primary 
EAA neurotransmitter. Although many investigators have demon- 
strated selective EAA receptor changes in AD in both cortex (22, 
23,57,58,59,62,72) and hippocampus (13,21,23,27,37,54), the 
results presented here provide the first comprehensive study of 
EAA receptor alterations in AD visual cortex. It is not known, 
however, at what point in the course of the disease that these 
alterations in EAA receptors become manifest. This is an impor- 
tant issue, for the fact that EAA receptor levels change with AD 
may only be a result of the neurodegenerative process and thus 
simply an effect of the disease, rather than an active cause. In 
future studies, an examination of the expression of the genes and 
proteins for EAA and GABA receptors is warranted to ascertain 
whether there may be a fundamental alteration in these receptors 
that precedes the overt pathology. These latter studies would have 
to be carded out in early AD cases or even in normal aging to 
determine the relationship of gene and protein expression to the 
progression of the disease. 
The laminar pattern of EAA and BDZ receptor binding within 
the primary and association visual cortices probably results in a 
heterogeneous character of EAA mediated neurotransmission 
within the laminar hierarchy of the visual cortex. Autoradio- 
graphic studies of neurotransmitter receptors can provide novel 
information about the anatomical and functional organization of 
the visual cortex and may provide insight into the AD neuropa- 
thology also seen in those same areas of visual cortex. Anatomical 
studies have indicated that the characteristic pathology of AD is 
often associated with EAA cortical association pathways (53,60). 
In our study, AMPA receptor losses do not parallel the pathology, 
suggesting that AMPA receptors do not play a direct role in the 
AD pathology. The significant alterations in glycine binding to the 
NMDA receptor complex observed in our study, however, are 
intriguing because NMDA receptors have been implicated in syn- 
aptic plasticity in the primary visual cortex (5,18). In addition, it 
has been speculated that EAA receptors may play a role in the 
generation of AD neuropathology, by nature of their excitotoxic 
potential (3,12,23,31,39,40,51,56). Thus, EAA receptor sites 
may be exploited therapeutically in the design of future treatment 
for AD. 
Modulatory Role of Glycine 
In light of these interpretations, it is interesting that glycine, of 
the four ligands examined in our study, most directly reflected the 
hierarchical pattern of AD neuropathology. The changes in glycine 
binding were significant while those of NMDA were not. Note, 
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however, that the addition of glycine to the incubation mixture 
enhances basal NMDA-sensitive glutamate binding (the so-called 
glycine-dependent NMDA receptor binding). We did not add gly- 
cine to the incubation media for the NMDA-sensitive glutamate 
binding assay. The addition of glycine to our glutamate assay may 
have resulted in a more significant decrease in NMDA receptor 
binding in the AD brains (57,58,59). A decrease in glutamate 
binding to the NMDA receptor in AD may in fact represent a 
reduction in the glycine enhancement of glutamate binding (62). 
Clearly, these modulatory interactions require further study. Nev- 
ertheless, these findings are provocative because of glycine's pro- 
posed role as a neuro-modulator (45). It has been suggested that 
the glycine allosteric site of the NMDA receptor could be targeted 
therapeutically for the possible treatment of neurodegenerative dis- 
orders such as AD (8,23,24). In response to this suggestion, recent 
reports have focused on glycine and found that its modulation of 
the NMDA receptor is in fact disrupted in AD (57,58,59,62). With 
the recent cloning of a family of NMDA receptors, it will be 
important to determine whether discrete subtypes of NMDA re- 
ceptors are differentially affected in AD (33,47,48). The discrete 
subtypes of the NMDAR2 genes and the various splice variants of 
the NMDAR1 gene have different sensitivities to glycine 
(33,47,65). Furthermore, recent in situ hybridization data would 
suggest that the different NMDAR2 genes and the different splice 
variants of the NMDAR l gene have unique distributions in brain 
(47,63). Perhaps cells that preferentially express one or the other 
of these subtypes are particularly vulnerable to the pathology of 
AD. With the new antibodies that are becoming available to ex- 
amine the localization of these subtypes and the in situ hybridiza- 
tion methods for determining their cellular localization, it should 
be able to address these possibilities in more detail. The previous 
studies (57,58,59,62), combined with the results presented here, 
provide data to support a therapeutic role for glycinergic drugs in 
AD. It has been suggested that perhaps a partial glycine agonist, a 
drug which combines the glycine agonist properties to potentially 
enhance cognition with the glycine antagonist properties to retard 
disease progression, may actually provide the best solution (24). 
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